Balyasny Asset Management’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.2M | Sell |
864,096
-74,094
| -8% | -$964K | 0.02% | 665 |
|
|
2025
Q1 | $9.94M | Buy |
938,190
+389,429
| +71% | +$4.12M | 0.02% | 653 |
|
|
2024
Q4 | $9.31M | Buy |
+548,761
| New | +$9.31M | 0.01% | 689 |
|
|
2024
Q3 | – | Sell |
-41,947
| Closed | -$1.02M | – | 1939 |
|
|
2024
Q2 | $1.02M | Buy |
+41,947
| New | +$1.02M | ﹤0.01% | 1231 |
|
|
2023
Q2 | – | Sell |
-107,653
| Closed | -$2.58M | – | 1842 |
|
|
2023
Q1 | $2.58M | Sell |
107,653
-896,582
| -89% | -$21.5M | 0.01% | 1031 |
|
|
2022
Q4 | $17M | Buy |
1,004,235
+664,852
| +196% | +$11.3M | 0.05% | 443 |
|
|
2022
Q3 | $5.03M | Buy |
339,383
+328,574
| +3,040% | +$4.87M | 0.02% | 756 |
|
|
2022
Q2 | $170K | Buy |
+10,809
| New | +$170K | ﹤0.01% | 1779 |
|
|
2020
Q4 | – | Sell |
-26,628
| Closed | -$1.14M | – | 1139 |
|
|
2020
Q3 | $1.14M | Sell |
26,628
-66,750
| -71% | -$2.86M | 0.01% | 757 |
|
|
2020
Q2 | $4.36M | Buy |
+93,378
| New | +$4.36M | 0.04% | 454 |
|
|
2016
Q2 | – | Sell |
-42,283
| Closed | -$1.12M | – | 977 |
|
|
2016
Q1 | $1.12M | Sell |
42,283
-62,761
| -60% | -$1.67M | 0.01% | 567 |
|
|
2015
Q4 | $4.62M | Buy |
105,044
+73,619
| +234% | +$3.24M | 0.03% | 445 |
|
|
2015
Q3 | $1.33M | Buy |
31,425
+4,429
| +16% | +$187K | 0.01% | 552 |
|
|
2015
Q2 | $1.24M | Buy |
+26,996
| New | +$1.24M | 0.01% | 565 |
|